Every week, about two dozen patients come to a small room in Frederiksberg Hospital, a maze of old red-brick buildings in central Copenhagen. They are blindfolded and told to insert earphones with music. Then a nurse injects them with what they hope is the blockbuster weight-loss drug Wegovy.
The patients are trying to shed an addiction, not unwanted pounds. They are volunteers in one of a growing number of studies begun in the U.S. and Denmark this year to see whether Wegovy can treat alcoholism.
Researchers are pushing the boundaries on a class of drugs that became famous for helping people lose weight, testing the shots across a spectrum of disorders from Alzheimer's disease to sleep apnea. The market for obesity and diabetes will probably soar above $140 billion by 2032, analysts at J.P. Morgan predict, with the potential for even more if the drugs prove medically versatile.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.